GFH018 5 mg BID 14d-on/14d-off (N = 4) n (%) | GFH018 10 mg BID 14d-on/14d-off (N = 3) n (%) | GFH018 20 mg BID 14d-on/14d-off (N = 4) n (%) | GFH018 30 mg BID 14d-on/14d-off (N = 7) n (%) | GFH018 40 mg BID 14d-on/14d-off (N = 4) n (%) | GFH018 50 mg BID 14d-on/14d-off (N = 4) n (%) | GFH018 65 mg BID 14d-on/14d-off (N = 6) n (%) | GFH018 85 mg BID 7d-on/7d-off (N = 6) n (%) | GFH018 85 mg BID 14d-on/14d-off (N = 12) n (%) | Total (N = 50) n (%) | |
---|---|---|---|---|---|---|---|---|---|---|
BOR | ||||||||||
CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SD | 0 | 1 (33.3%) | 1 (25.0%) | 1 (14.3%) | 0 | 1 (25.0%) | 1 (16.7%) | 1 (16.7%) | 3 (25.0%) | 9 (18.0%) |
PD | 2 (50.0%) | 2 (66.7%) | 1 (25.0%) | 3 (42.9%) | 3 (75.0%) | 1 (25.0%) | 5 (83.3%) | 2 (33.3%) | 4 (33.3%) | 23 (46.0%) |
NE | 0 | 0 | 1 (25.0%)e | 0 | 0 | 0 | 0 | 0 | 0 | 1 (2.0%)e |
Non-CR/Non-PDa | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAb | 2 (50.0%) | 0 | 1 (25.0%) | 3 (42.9%) | 1 (25.0%) | 2 (50.0%) | 0 | 3 (50.0%) | 5 (41.7%) | 17 (34.0%) |
ORR (90%CI)c | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DCR (90%CI)d | 0 | 1 (33.3%) (0.84%, 90.57%) | 1 (25.0%) (0.63%, 80.59%) | 1 (14.3%) (0.36%, 57.87%) | 0 | 1 (25.0%) (0.63%, 80.59%) | 1 (16.7%) (0.42%, 64.12%) | 1 (16.7%) (0.42%, 64.12%) | 3 (25.0%) (5.49%, 57.19%) | 9 (18.0%) (8.58%, 31.44%) |